Related Experiment Video

Updated: Sep 27, 2025

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

1.7K

Second-Generation JK-206 Targets the Oncogenic Signal Mediator RHOA in Gastric Cancer

Myeonghun Beak1, Sungjin Park2,3, Jin-Hee Kim4

  • 1College of Medicine, Gachon University, Incheon 21565, Korea.

Cancers
|April 12, 2022
PubMed

Insights

Novel RHOA inhibitors, JK-206 and JK-312, show potential against gastric cancer (GC). JK-206 may offer a new therapeutic strategy by inhibiting GC cell proliferation and migration via the mitogenic pathway.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Ras homologous A (RHOA) is a GTPase implicated in gastric cancer (GC) progression.
  • Gastric cancer is a leading cause of cancer-related mortality worldwide.
  • Previous research identified RHOA inhibitors JK-136 and JK-139.

Purpose of the Study:

  • To optimize RHOA inhibitors for enhanced anti-gastric cancer (GC) potency.
  • To evaluate novel RHOA inhibitors, JK-206 and JK-312, for their efficacy against GC cell lines.

Main Methods:

  • Lead optimization of RHOA inhibitors.
  • In vitro testing of compounds JK-206 and JK-312 on GC cell lines to assess viability and migration.
  • Transcriptomic analysis of GC cells treated with JK-206.

Main Results:

  • Compounds JK-206 and JK-312 demonstrated significant inhibition of GC cell viability and migration.
  • Transcriptomic analysis revealed that RHOA inhibition by JK-206 is linked to the suppression of the mitogenic pathway.
  • These findings suggest a mechanism for the anti-cancer effects of RHOA inhibition.

Conclusions:

  • Novel RHOA inhibitors, particularly JK-206, show promising anti-gastric cancer (GC) activity.
  • Targeting RHOA represents a potential therapeutic strategy for managing GC proliferation and migration.
  • Further investigation into JK-206 and its effects on the mitogenic pathway is warranted for GC treatment development.
Keywords:
JK-206RHOARhosingastric cancerpharmacogenomicstranscriptomics

More Related Videos

RhoC GTPase Activation Assay09:58

RhoC GTPase Activation Assay

Published on: August 22, 2010

12.6K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.9K

Related Concept Videos

Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.5K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K